DKTK-Studienregister

Detailsuche

Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.

» Hämatologische Neoplasien » CML

Alle Linien

CMLXI
Frontline Asciminib Combination in Chronic Phase CML (CMLXI) (Aktiv)

Erstlinie

FASCINATION
FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CML FASCINATION (CML STUDY XI) (Aktiv)

Zweitlinie oder später

CA180-406 CML
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation (Aktiv)

CABL001E2201
Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib (Aktiv)

CAMN107A2408 (ENESTop)
Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (Aktiv)

CSTI571ADE60_CML
Dendritic Cells as Autologous Vaccine (Aktiv)

ELVN-001
A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia (Aktiv)

H3 Biomedicine
Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (Aktiv)

ML DS 2018
Phase II/III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018 (Aktiv)

Novartis DFV890
A phase 1b, open label, multi-center, dose optimization and dose expansion study to assess the safety and efficacy of DFV890 in adult patients with myeloid diseases. (Aktiv)

Ruxo-BEAT
Ruxolitinib im Vergleich zur besten verfügbaren Therapie in Patienten mit Hoch-Risiko Polycythemia vera oder Hoch-Risiko Essentieller Thrombozythämie – Die RUXO-BEAT Studie (Aktiv)